english.prescrire.org > Prescrire International > N°250 - July 2023

n°250

July 2023

Issue Contents
Editorial

Free  Interdisciplinary collaboration

p.171

Marketing Authorisations


Daridorexant (Quviviq°) in insomnia

p.173-177
Evaluation not designed to demonstrate a therapeutic advance

Editors' opinion. New is not necessarily better

p.175

Mepolizumab (Nucala°) in nasal polyposis

p.177

Lenvatinib (Lenvima°) + pembrolizumab (Keytruda°) in advanced or relapsed endometrial cancer

p.178

Ozanimod (Zeposia°) in ulcerative colitis

p.179-180

Eptinezumab (Vyepti°) for prevention of migraine attacks

p.180

Daratumumab (Darzalex°) in systemic light chain amyloidosis

p.181

Ustekinumab in Crohn's disease

p.182
No more effective than adalimumab, but a few differences in the frequency of various adverse effects

Secukinumab (Cosentyx°) in some types of juvenile arthritis

p.183

Doravirine alone (Pifeltro°) or in combination (Delstrigo°) for HIV infection in adolescents

p.183

Niraparib in ovarian cancer: indications restricted in the US, a measure also warranted in the EU

p.184

Adverse Effects


Venlafaxine during the first trimester of pregnancy: possible risk of birth defects, especially cardiac malformations

p.185-186

Sclerosants for varicose veins: thrombo­embolism and cardiac arrhythmias

p.187-188

Ibuprofen + codeine in the same tablet: fatal renal and gastro­intestinal adverse effects

p.188

Diltiazem + a direct-acting anti­coagulant: serious bleeding

p.189

Common stem: -kef-

p.189

Outlook


"Hybrid closed-loop" systems for blood glucose control in type 1 diabetes

p.190-194
Another way of delivering intensive insulin therapy

Inset. What are hybrid closed-loop systems for blood glucose control, and how do they work?

p.191

The evaluation of drugs to treat type 2 diabetes

p.194

Free  Clinical trials in children: many results go unreported

p.195

Masthead


Free  Masthead

p.170

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe